Open AccessComprehensive assessment of levodopa-carbidopa intestinal gel for Turkish advanced Parkinson’s disease patients
Author(s) -
Yeşim Sücüllü Karadağ,
TuGÇe SaltoGlu,
FadIme ErdoGan KÜÇÜkdaGli,
Ömer Öztürk,
Hasan Tankut Köseoğlu,
Emin Altıparmak
Publication year - 2021
Publication title -
turkish journal of medical sciences
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.277
H-Index - 27
eISSN - 1303-6165
pISSN - 1300-0144
DOI - 10.3906/sag-2005-96
Subject(s) - medicine , turkish , levodopa , carbidopa , disease , parkinson's disease , gastroenterology , philosophy , linguistics
Levodopa-carbidopa intestinal gel (LCIG) is an effective treatment modality in the management of advanced Parkinson’s disease (PD) despite frequent adverse events and different rates of dropouts. Efficacy and safety data regarding Turkish patients on LCIG are limited. This study aims to report in detail the efficacy and adverse effect profile of LCIG among advanced PD patients from a Turkish center for movement disorders.